Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about mci: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| A4 Trial | Anti-Amyloid treatment in asymptomatic MCI (preclinical AD) |
| DIAN-TU | Disease-modifying therapies in autosomal dominant AD with MCI endpoints |
| Disease modification in early stages | Lecanemab and donanemab trials demonstrated greatest benefit in MCI/early AD populations[@cummings2024] |
| Biomarker-driven enrollment | Amyloid PET, CSF p-tau217, and blood-based biomarkers enabling precise patient selection[@Hansson2024] |
| Prevention trials | A4 study and DIAN-TU established frameworks for secondary prevention |
| Combination approaches | Amyloid removal + neuroprotection + lifestyle interventions |
| Blood-based biomarkers | p-tau217, p-tau181, NfL, GFAP — enabling non-invasive screening |
| Amyloid PET | Established enrollment criteria, becoming more accessible |
| Tau PET | Patient stratification and treatment response monitoring |
| Fluid biomarkers | CSF alpha-synuclein for MCI with Lewy body features |
| 2024-2025 | Anti-amyloid market driven by lecanemab and donanemab uptake |
| 2026-2028 | Expected $5-8B annual market for early AD/MCI treatments |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
Knowledge base pages for this entity
graph TD
A["Genetic risk factors"] --> B["mci"]
C["Environmental factors"] --> B
B --> D["Protein aggregation"]
B --> E["Neuroinflammation"]
D --> F["Neuronal loss"]
E --> F
F --> G["Clinical symptoms"]
classDef disease fill:#3a1a1a,stroke:#ef5350,color:#e0e0e0
classDef mechanism fill:#2a2a1a,stroke:#ffd54f,color:#e0e0e0
class B disease
class D,E mechanism| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| h-527d32c9 | biomarker_for | hypothesis | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Closed-loop transcranial focused ultrasound with 40Hz gamma | 1.000 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-25 | 6 hypotheses Top: 0.583
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Epigenetic clocks association with brain aging patterns in older women | exploratory | cognitive impairment and demen | 0.900 | 0.00 | human patients | proposed | N/A |
| Brain Connectivity-Targeted tACS Trial in Early AD | clinical | Alzheimer's Disease | 0.509 | 0.50 | human postmortem brain tissue | proposed | $520,000 |
| Brain Connectivity-Targeted tACS Trial in Early AD | clinical | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $730,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| A therapeutic small molecule enhances γ-oscillations and improves cognitio [PMID:39106304] | Unknown | Proceedings of the National Ac | 2024 | 0 |
| Parvalbumin Interneuron Dysfunction in Neurological Disorders: Focus on Epilepsy [PMID:38791587] | ["Leitch B"] | International journal of molec | 2024 | 0 |
| Transcranial alternating current stimulation (tACS) at gamma frequency: an up-an [PMID:38926897] | De Paolis ML, Paoletti I, Zaccone C | Transl Neurodegener | 2024 | 0 |
| Gamma frequency entrainment attenuates amyloid load and modifies microglia. [PMID:27929004] | ["Iaccarino H", "Singer A", "Martorell A | Nature | 2016 | 0 |
| Inhibitory interneuron deficit links altered network activity and cognitive dysf [PMID:22541439] | Verret L, Mann EO, Hang GB, Barth AM, Co | Cell | 2012 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning mci in their description or question text
No additional research found